Citius Pharmaceuticals Reports Positive Early Stage Results of Cancer Combo Treatment

Seeking Alpha11/11 23:47

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients With Recurrent Solid Tumors

PR Newswire11/11 21:45

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga10/22 04:31

Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement

Benzinga09/13 20:40

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire09/06 04:30

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

PR Newswire09/05 20:30